Video

Defining Resectability in CSCC

Author(s):

Nikhil Kushalani, MD,Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute

Following their discussions on staging and risk stratification in CSCC, key opinion leaders work to define resectability in cutaneous squamous cell carcinoma.

Related Videos
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Thach-Giao Truong, MD, medical director, Melanoma Program, Cleveland Clinic
5 KOLs are featured in this series.
Related Content
Martin Wermke, MD
October 10th 2024

IMA203 Displays Efficacy in Heavily Pretreated Melanoma

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Meredith McKean, MD, of Sarah Cannon Research Institute
September 16th 2024

Fianlimab/Cemiplimab Demonstrates Persistent Activity in Advanced Melanoma, Independent of LAG-3 and PD-L1 Status

Blessy Mathew Jacob, MD; Ana Van Der Wall, MD; Vance M. Wright-Browne, MD
February 8th 2024

Community Oncologists on the Importance of Self-Reliance and Collegial Trust as Women in Medicine

Caroline Robert, MD, PhD
September 15th 2024

RP1 Plus Nivolumab Demonstrates Durable Antitumor Activity in Advanced Melanoma

Caroline Robert, MD, PhD
September 15th 2024

Long-Term KEYNOTE-006 Data Support Pembrolizumab as SOC in Advanced Melanoma